Evidence map›Paper›PMID 36539575›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2023

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.

Nicholas Coupe, Lina Guo, Esther Bridges, Leticia Campo, Olivia Espinosa, Richard Colling, Andrea Marshall, Ashwin Nandakumar, Ruud van Stiphout, Francesca M Buffa and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Role of the Ror family receptors in Wnt5a signaling.In vitro cellular & developmental biology. Animal · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Nicholas CoupeDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK. nicholas.coupe@ouh.nhs.uk.
Lina GuoDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Esther BridgesDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Leticia CampoDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Olivia EspinosaDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
Richard CollingDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
Andrea MarshallWarwick Clinical Trials Unit, Division of Health Sciences, University of Warwick, Coventry, UK.
Ashwin NandakumarNuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Ruud van StiphoutDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Francesca M BuffaDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Pippa G CorrieDepartment of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
Mark R MiddletonDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
Valentine M MacaulayDepartment of Oncology, Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, OX3 7LJ, UK. valentine.macaulay@nds.ox.ac.uk.
University of Oxford · GBChurchill Hospital · GBJohn Radcliffe Hospital · GBAddenbrooke's Hospital · GBUniversity of Warwick · GB

Funding

ARTICULATE PRO Al AWARD02269Cancer Research UK CRUKDF 0317-NCNIHR Cambridge Biomedical Research Centre BRC-1215-22214Oxford pathLAKE Centre of Excellence 104689Oxfordshire Health Services Research Committee EC/1150
6 · The paper itself

Abstract

purposeDespite recent advances, approximately 50% of patient with metastatic melanoma eventually succumb to the disease. Patients with melanomas harboring a BRAF mutation (BRAF

methodsWe investigated this finding in vitro and in vivo using melanoma cell lines and clones generated by BRAF

resultsCompared with BRAF

conclusionsThese data implicate WNT5A-ROR2 in VEGF secretion, vascularity, adverse outcomes and bevacizumab sensitivity of BRAF

Indexed as

MelanomaProto-Oncogene Proteins B-rafReceptor Tyrosine Kinase-like Orphan ReceptorsWnt-5a ProteinBevacizumabCell Line, TumorHumansMitogen-Activated Protein Kinase KinasesMutationVascular Endothelial Growth Factor ABevacizumabBRAF protein, humanMitogen-Activated Protein Kinase KinasesProto-Oncogene Proteins B-rafReceptor Tyrosine Kinase-like Orphan ReceptorsROR2 protein, humanVascular Endothelial Growth Factor AWnt-5a ProteinWNT5A protein, humanBevacizumabBRAFMelanomaROR2WNT5A

Identifiers

PMID36539575
PMCPMC10060292
OpenAlexW4312067617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.